Longer temporal interaction between CAR T-cells and TP53-deficient AML/MDS leads to enhanced CAR T-cell exhaustion, reduced CAR T-cell proliferation, and eventually an overall decrease in AML cell killing and leukemia cell outgrowth (Fig. 7). This evidence concerns the gene TP53 and myelodysplastic syndrome.